US Patent

US11752199 — Methods of modulating pericytes

Method of Use · Assigned to Mallinckrodt Ard Ip Unlimited Co · Expires 2041-07-18 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of modulating pericytes in subjects who need it.

USPTO Abstract

The present disclosure is directed to methods of modulating pericytes in subjects in need thereof.

Drugs covered by this patent

Acthar Gel (CORTICOTROPIN) · Mallinckrodt Ireland

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3686`	—	Acthar Gel
`U-3686`	—	Acthar Gel
`U-3686`	—	Acthar Gel

Patent Metadata

Patent number: US11752199
Jurisdiction: US
Classification: Method of Use
Expires: 2041-07-18
Drug substance claim: No
Drug product claim: No
Assignee: Mallinckrodt Ard Ip Unlimited Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.